BCF Technology has launched a competition in which the person who submits the best photograph with the theme of: All in a day's work - animal imaging, will win an iPad 2.
To enter the competition, you need to post your photographs, (and tell BCF a little about the story behind the images) at www.facebook.com/bcftechnology or email them to: info@bcftechnology.com
Jason Rogers, Marketing Manager at BCF said: "We wanted to create a fun way to show just how interesting and different each days work is when imaging animals. We have made the competition open to all that work with animal imaging including our staff, dealers and vets, vet nurses, animal contractors, etc from all over the world.
"It is great to see the BCF office in the States and our international dealers also promoting the competition in their own countries, making the competition truly international. Response to the competition has been fantastic - see our facebook page to some entries for yourself."
The closing date for the competition is 30th September 2011.
For more information, visit: www.bcftechnology.com
The University of Liverpool’s Philip Leverhulme Equine Hospital has installed a standing equine MRI scanner from Hallmarq Veterinary Imaging.
Equine vets and farriers in South Wales who need horses x-rayed can now use a new mobile service offered by Equiray. Operating 24 hours a day, 7 days a week, Equiray's technicians travel to the site to take digital x-rays, using state-of-the-art imaging equipment.
At the heart of Equiray's service is the Uno Equine portable digital x-ray system; the only system in the world that has a capture screen built into the generator. All images taken can be viewed within minutes and decisions made there and then regarding further tests. The x-ray images are emailed to the veterinary surgeon immediately, or supplied to the practice on a CD or memory stick. They are also stored securely by Equiray for a 3 month period.
For farriers, the image can be displayed on screen so they can see the internal bone structures encapsulated within the hoof before they start remedial work, and then another x-ray taken after the work has been completed. Both images can be viewed together for comparison.
Equiray says its service means practices don't have to buy and maintain costly equipment, nor send a practice technician to attend with the vet, as all Equiray technicians are highly skilled in equine imaging.
Equiray currently operates mainly in South Wales but with requests coming from other areas of the country, the company says its technicians are travelling to x-ray several horses in a particular area, over a 2 day period. Remedial farriers requiring monthly x-rays of certain horses are also using the service and plans to extend the service nationally are in progress.
For more information, visit www.equiray.co.uk/
Britain's leading equestrian organisations are conducting a survey to find out more about the welfare standards in livery yards. Livery yards are very popular in the UK for those people who are unable to keep their horses and ponies at home. However, there is no record of how many horses are currently at livery or indeed the number of operating yards and the welfare standards under which they operate. Representatives from the British Equine Veterinary Association (BEVA), World Horse Welfare, The British Horse Society, RSPCA, Association of British Riding Schools, South Essex Insurance Brokers (who currently insure a total of 8,562 DIY and livery stables), and for local government LACORS and CIEH, set up a working party to carry out some research into UK livery yards to become better informed about standards. The group took the view that asking vets and the public about their local livery yard would help to obtain information about the number of yards and get a general picture of the range and standard of accommodation and services that livery yards offer. Veterinary surgeons, horse owners, grooms, yard owners, farriers and other equine professionals are invited to complete the online survey at http://www.liveryyardsurvey.co.uk/. Please complete a survey for each livery yard about which you have first hand knowledge. Your answers will remain confidential, and the results will be reviewed in September 2008 to establish what further action, if any, is necessary.
The module, which accounts for one hour’s CPD, is facilitated by a Boehringer Ingelheim territory manager and presented by Dr Tim Brazil BVSc, PhD, CertEM, DECEIM, MRCVS, a leading expert in equine internal medicine.
Boehringer says the presentation will help refresh veterinary professionals’ knowledge on equine lower respiratory tract disease, including Recurrent Airway Obstruction (RAO), and encourage them to feel confident and fully equipped to deal with this common respiratory scenario in practice.
During the module, attendees will be guided through two common equine respiratory cases and encouraged to discuss potential approaches to diagnosis, treatment and management in the cases he describes. The module is supported by supplementary notes which can be referred to both during and after the presentation.
Additional webinars on equine respiratory disease are also available on the Boehringer Academy website. They include: Diagnosing equine lower airway disease by Scott Pirie, Managing infectious respiratory disease by Phil Ivens, Clinical diagnostics and management of acute respiratory distress by Tim Brazil and Treatment of inflammatory airway disease by David Rendle.
To book your in-practice CPD meeting, contact your local Boehringer Ingelheim territory manager.
To view the equine respiratory disease webinars, visit www.boehringer-academy.co.uk and search for 'Inspiring CPD'.
Eurovet has launched Relaquine 35 mg/ml Oral Gel for Horses - a licensed acepromazine (ACP) in a gel format.
The company says Relaquine can be used to sedate horses for examination and in stressful situations that some horses find hard to deal with such as farriery, box rest, dentistry and clipping where highly-strung horses can cause problems. Relaquine is administered orally or mixed with food and is available as an adjustable syringe format containing 10 ml of gel.
Relaquine is the fourth product launch this year by Eurovet and the company says there is more in the pipeline for 2011.
Relaquine Oral Gel is expected to be available to order from veterinary wholesalers from Monday 16th May. Eurovet is also offering an introductory promotion: for further details contact Eurovet on 01223 257933.
The MSD Animal Health Vet Surgeon Research Bursary offers awards of up to £4,000 each. Each project has to be completed within one to two years and the veterinary surgeon proposals are judged by university academics to ensure independent assessment.
Michelle Townley, veterinary advisor at MSD Animal Health said: "We’re delighted to be awarding Amie this bursary as we consider deepening the understanding of equine vaccination practices and protocols to be important new knowledge for the companion animal sector, especially in the light of the recent equine flu outbreak.
"We will be inviting applications for the 2019 vet surgeon bursaries from August this year so would encourage any vet keen to develop their research skills to keep an eye on our website for further information. We would like to encourage as many vets as possible to apply as part of our commitment to advancing research within the veterinary industry."
2018 is the second year MSD Animal Health has extended its Veterinary Surgeon Research Bursary to include companion animals. The 2017 award went to Dr Sarah Caddy for her research into cat bite abscesses.
Veterinary surgeon research bursary applications will open again in August.
For more information, visit www.msdahresearchbursary.co.uk.
Intervet/Schering-Plough Animal Health has announced that it is re-introducing Equilis StrepE, the only strangles vaccine for horses in Europe. The vaccine was voluntarily withdrawn from the market in 2007 for stability reasons.
Equilis StrepE, which has already been relaunched in the Netherlands, is now scheduled to arrive in Italy in September and the United Kingdom in October this year. Further re-launches in European countries are scheduled later in 2010 and beyond.
According to Intervet/Schering-Plough, three years of additional research and development have resulted in several improvements to the vaccine, including a better manufacturing process to ensure that the product maintains its characteristics throughout its shelf-life. A more user-friendly applicator has been developed, which enables the needle to slot into place, thereby making it easier to administer the vaccine.
Equilis StrepE is administered through a submucosal injection in the upper lip of the horse and provides immunity for three months following two initial injections, four weeks apart. The vaccine significantly reduces clinical signs of strangles and occurrence of lymph node abscesses in horses that are at risk of infection.
Dr. Peter Daels, veterinarian at the Keros Insemination and Embryo Transfer Center in Beselare (Belgium) said: "In our recipient embryo transfer herd, we have used this strangles vaccine on over 500 mares. After a few applications, the vaccine was easy to administer and did not cause any serious side effects. Despite a steady flow of new horses, only eight cases of strangles were noted - all were mild and most were newly acquired horses that had apparently been exposed shortly before vaccination. I believe that the vaccine provided solid protection against the disease, reduced the severity of clinical cases and eliminated the risk of a widespread outbreak in our herd."
Dr. Roberto Ragni-Alunni, Global Technical Manager Equine at Intervet/Schering Plough Animal Health said: "The re-launch of Equilis StrepE in Europe is an important milestone in our efforts to fully meet the needs of our customers in the equine industry. We continue to work in a very intense and comprehensive way to ensure adequate supply of our equine vaccine range".
The British Equine Veterinary Association (BEVA) has launched two guides to help veterinary professionals and their clients negotiate the complexities of equine insurance.
BEVA highlights that with up to 40% of horses becoming ill or injured in any one year and 25% of insured horses having a claim in any one year, vet fees insurance is a sensible way for horse owners to budget for unexpected healthcare costs.
The Veterinary Surgeon's guide to riding and sport horse insurance provides general guidelines to help vets understand the requirements and issues relating to equine insurance. It explains the three main types of insurance cover available: veterinary fees, death and permanent loss of use, as well as insurance recommendations for pre-purchase and pre-insurance vetting. The final section contains a jargon-busting guide to commonly used insurance terminology.
Complementing the vet guide is The BEVA leisure and sports horse Insurance Guide for horse owners, a handout for clients about to embark on taking out insurance. It covers the frequently asked questions relating to vets fees and death, including when and how to insure, the importance of pre-purchase vetting, exclusions and permanent loss of use.
Andrew Harrison, Junior Vice President of BEVA, said: "Whether a vet or a horse owner, understanding equine insurance can be intimidating for the best of us. The new guides should make it easier for you and your clients to understand the finer points of policies, premiums and claim protocols."
The guides can be downloaded from the BEVA website via the following links:
For additional information visit www.beva.org.uk
Kruuse UK has announced the launch of its new Mud Fever Kits for horses.
Kruuse says the launch follows independent studies last year by Aimi Duff BVM&S, MRCVS (Scott, Mitchell & Associates, Hexham) on the use of Manuka ND dressings for the treatment of Mud Fever.
The kit contains one complete treatment for two legs (or two complete treatments for one leg) including all dressings. There is also a step-by-step guide from the "Ask the Vet" series which explains best treatment protocol, designed to help veterinary surgeons dispense the kit directly to clients with confidence.
According to the company, the benefits of using medical grade Manuka Honey in the treatment of Mud Fever include:
Andrew Groom, Managing Director of Kruuse UK Ltd said: "We are delighted with the initial response to our unique Mud Fever Kits; such additions to our range continue to enhance the Kruuse commitment to equine wound care."
Vets with Horsepower is organised annually by Professor Derek Knottenbelt to help raise funds for equine and human charities around the world.
This year the group undertook an endurance motorbike trip of over 1600 miles: from the UK to Germany, across Scandinavia and back, hosting education events for equine vets along the way to raise funds for four charities including BEVA's Power for Ukraine.
BEVA Council member Alison Talbot, said: “Thanks to the generosity of equine vets in the UK we had just hit the halfway mark of raising £10,000, before Vets with Horsepower set off on their epic Scandinavian mission.
"We are so grateful for their donation of £9922 which means we can now buy another five generators, to help twice as many vets and horses in extremely difficult circumstances during enforced power cuts."
The generators will be transported to a collection point in Poland and then on to Ukraine in time for winter.
Donations to the BEVA Trust Power To Ukraine appeal can be made here: https://www.justgiving.com/campaign/powertoukraine
Any surplus funds will be added to the general fund to support equids in Ukraine.
A new scholarship on Equine Emergency and Critical Care has been started at a specialist equine hospital in County Kildare, at the heart of Ireland’s horse-racing district. Anna Hollis is the recipient of the scholarship, which is the first of its kind in Europe.
The scholarship gives her the opportunity to specialize in the field of emergency and critical care and to be Board Certified by the American College of Veterinary Emergency and Critical Care (ACVECC). The scholarship has been funded by a grant from Intervet/Schering-Plough Animal Health.
Anna Hollis (BVet Med, MRCVS) will receive the scholarship, for a duration of two years. Hollis just completed a residency in Medicine at the University of Pennsylvania (New Bolton Center) and already has several publications. She will be under the supervision of Kevin Corley (BVM&S PhD DECEIM DACVIM DACVECC MRCVS), an expert in the field of equine medicine and Board Certified by the ACVECC who is in charge of emergency and critical care at a large equine hospital in the Curragh area of County Kildare, Ireland.
Anna Hollis will be spending several rotation periods in various institutions in Europe and the USA, before taking the board examination for the ACVECC. This is the only equine Emergency and Critical Care residency in the European Union that is recognized by the ACVECC and one of the few in the world taking place at a private institution.
Intervet/Schering-Plough Animal Health is supporting this two-year initiative, “We are very excited to be working with Dr. Corley to establish this scholarship,” said Roberto Ragni-Alunni, Global Technical Manager for the equine business in Intervet/Schering-Plough Animal Health. ”The research offers the possibility to reach a rare level of specialization. This will benefit critically ill horses and help push the boundaries of equine medicine even further.”
The oral corticosteroid powder formulation was previously only available in 180g tubs.
Severe equine asthma, which was previously known as Recurrent Airway Obstruction (RAO), Chronic Obstructive Pulmonary Disease (COPD) or Heaves, can lead to airway neutrophil influx and excessive mucus production. Although it is generally managed by environmental measures to suppose triggering factors, it can be combined with corticosteroid therapy to control airway inflammation in more severe cases.
Alana McGlade BVMedSci BVM BVS MRCVS, Equine Business Manager, said: "Severe equine asthma is the most common cause of chronic coughing in mature horses. Attributed to a hypersensitivity to inhaled allergens and dust, clinical signs - such as inflammation of the airways - can be alleviated by Equisolon’s active ingredient prednisolone.
"Prednisolone has been shown to have positive effects on clinical signs, endoscopic evaluation, arterial blood gases and pulmonary function when used in conjunction with environmental changes to reduce a horse’s exposure to potential triggers.
"Previously, vets would have had to measure out the powder but the sachets make dosing more convenient. The sachets come in a box of 10, so each pack will treat one 300 kg horse for 10 days or one 600 kg horse for 5 days. As the sachets are pre-measured, horses get exactly the dose they need.”
Equisolon oral powder contains 33.3 mg/g of prednisolone and should be administered at 1 mg prednisolone per kg of body weight per day. Treatment can be repeated at 24 hour intervals during 10 consecutive days.
For more information visit www.dechra.co.uk
They say that they've been aware of minor interruptions to the supply of such vaccines throughout 2022.
However, a significant, pan-European logistical problem being experienced by Boehringer Ingelheim has raised the prospect of a further reduction in supplies in the coming months.
BEVA is liaising with the three vaccine manufacturers to quantify the impact of the shortage and to consider solutions, both to minimise the threat to equine health and to prevent disruption to equestrian competition.
Marc Laemmer, equine business head at Boehringer Ingelheim Animal Health, said: “We are currently experiencing a European-wide supply issue relating to our equine influenza and influenza-tetanus vaccines.
"This has been caused by unexpected issues following the implementation of a technology upgrade and is not a product or quality issue.
"This means that some vet practices will have difficulty obtaining sufficient influenza vaccines and there may be a shortage in the UK market.
"We understand the importance of these vaccines to equine welfare, and we are continuing to work tirelessly to find a solution so that we can return to normal supply as soon as possible.”
Amanda Melvin, equine business manager at MSD Animal Health, said: “Based on prior demand, MSD’s equine vaccines Equilis Prequenza and Equilis Prequenza Te are in full supply.
"MSD have taken steps to protect as many horses as possible at this time.
"We will continue to supply existing customers with the available MSD stock on ‘allocation’ and, where possible, to allocate stock to additional customers. Allocations are being made to our veterinary customers based on their historical demand which we believe is the most efficient way to manage the available supplies.”
Rebecca Cabrejas, equine business unit manager at Zoetis, said: “Demand for our vaccines currently exceeds what we can supply.
"Whilst we have adequate stocks to fulfil current customers’ orders unfortunately, we are not in a position to be able to supply new customers at this time.
"We will continue to work with BEVA to limit the impact of the current shortages.”
The Arthrex Vet Systems Mobile Lab will be hosting hands-on sessions to help practitioners develop their arthroscopy and joint block skills in its state-of-the-art laboratory.
BEVA President Roger Smith said: “Our practical sessions are always highly popular and the wetlab experience takes things to the next level."
"The ability to practice ultrasound-guided injections at the conference provides the opportunity to hone your skills in ultrasound and enable you to cement to ultrasound-guided injections of tendons and ligaments and joints into your daily practice.
On the Thursday there will be three wetlab taster sessions at three different stations, giving delegates the chance to sharpen their skills with an ultrasound scanner, arthroscope and arthrobox.
Friday’s sessions will be focused on forelimb joint blocks and arthroscopic demonstrations of the needle locations.
The full BEVA Congress programme is now live and super early bird tickets are available until 7th June 2024.
Individual super early bird BEVA members prices are £524 for vets and £144 for vet nurses for all three days (with concessionary available for those in their first three years of graduation or earning less than £25,000).
Day tickets and practice passes are also available.
http://www.bevacongress.org
Boehringer Ingelheim has launched Care and Connect a free online PPID aftercare service for horse owners, designed to help veterinary practices monitor their PPID case load and streamline the case management process.
The new service is part of Boehringer's 'Talk About Laminitis (TAL)' Awareness campaign.
The company says that PPID is the sixth most frequently encountered disease syndrome affecting equids in the UK1, and the new service should help engage owners and vets post diagnosis, thereby maximising treatment success.
Liz Barrett, equine business manager at Boehringer, said: “PPID is a progressive disease, so it is vital that veterinary surgeons remain at the centre of care, and that horses are monitored carefully following their initial diagnosis. However we recognise the high administrative demand associated with this, and TAL Care and Connect has been designed to reduce this as much as possible.”
TAL Care and Connect will be offered automatically to horse owners who take advantage of this year’s free* ACTH testing scheme, which will be available from July to November. Equine practices can also offer this aftercare service to all owners of previously diagnosed PPID cases.
Owners who join TAL Care and Connect will be able to set up a profile for their horse which allows all their ACTH results to be stored in one place. They will then receive the relevant reminders for follow-up ACTH testing which will make it easier for vets to monitor their patient’s progress over time.
In addition, owners can download an independently-written PPID information pack. Edited by Prof. Catherine McGowan with contributions from Dr Jo Ireland, Prof. Andy Durham, David Rendle and Dr Teresa Hollands, the pack includes advice on monitoring and follow-up ACTH tests, feeding, general care of the PPID patient and the link between laminitis and PPID.
Talk About Laminitis is supported by Redwings, The British Horse Society and World Horse Welfare, and will run from July until the end of October 2015. Horse owners can find out more and obtain their free ACTH voucher code at www.talkaboutlaminitis.co.uk.
For further information contact your local Boehringer territory manager or visit www.talkaboutlaminitis.co.uk.
*Cost of laboratory test
References
The webinar, which is presented by equine internal medicine specialist David Rendle from Rainbow Equine Hospital, challenges some of the current perceptions of worm control in horses and explains why veterinary surgeons need to engage more with horse owners on the topic to ensure a sustainable approach to parasite control.
Supported by Virbac, maker of Equimax and Eraquell horse wormers, the webinar is free to BEVA members at http://www.ebeva.org/webinar74.
The first, carried out by Nanna Luthersson and colleagues and published online in the Journal of Equine Veterinary Science in March, evaluated the laminitis risk factors in a group of Danish horses and ponies.1 It confirmed that Cold-blooded type animals <149cm, such as certain native ponies, as well as those being kept on high quality pasture were at an increased risk of developing laminitis for the first time. It also highlighted the important role that a change in grass intake, in terms of both type and amount, may play at any time of the year not only the spring as commonly thought.
The second study, funded in part by the PetPlan Charitable Trust, British Veterinary Association Animal Welfare Foundation Norman Hayward Fund and the Laminitis Trust, was undertaken in conjunction with Nicola Menzies-Gow (Royal Veterinary College) and published online in the Equine Veterinary Journal (EVJ) in August. The study evaluated the risk factors for the development of laminitis prior to the occurrence of the disease.2 It identified that low concentrations of the adipose tissue derived hormone adiponectin, together with high serum insulin concentrations (at rest and as part of a diagnostic test for PPID) may predict an increased risk of future pasture-associated laminitis.
It is hoped that future studies will be able to generate more robust cut off values, which will more accurately predict future laminitis development in an individual animal.
The RVC in collaboration with Waltham is now taking this forward through a study in which these markers are measured regularly, in conjunction with a detailed management assessment, in a group of ponies with no known history of laminitis at the start.
Clare Barfoot RNutr and the research and development manager at Spillers said: "The Danish study gives us important practical facts about the susceptibility of cold-blooded types, and is particularly applicable to natives in the UK. The second study gives hope that there may soon be a test or series of tests that will help predict those at an increased risk of suffering from pasture associated laminitis in the future thereby reducing the number of animals affected by this debilitating condition. In the meantime until we fully understand the condition it is sensible to manage all the risk factors we currently know about, in particular keeping your horse at a healthy weight."
To nominate someone for inclusion in the showcase, visit: https://www.beva.org.uk/60-Faces
BEVA President Lucy Grieve said: "We are proud of BEVA’s heritage and want to recognise our 60th birthday by celebrating some of those who have made a significant difference to the equine veterinary community. We want you to help us identify the 60 individuals who you believe have truly inspired, influenced and progressed the equine veterinary profession for the better.”
Each of the nominated 60 faces will be highlighted on the website and on BEVA’s social media channels. Profile details will include career paths, workplaces and personal contributions to the equine veterinary profession.
Lucy added: "We have already started the list with Colonel John Hickman, Sue Dyson and Peter Rossdale. But there are hundreds of exceptional, deserving individuals who have made a huge difference to the equine veterinary profession and are worthy of our 60 Faces roll call."
The deadline for nominations is Friday 16th April 2021. All nominations are anonymous.
The company warned last year that Equip Artervac would be out of stock from the end of November 2017 until mid-2018, but says that the re-availability of the vaccine means many vaccinated stallions and teasers should now be able to have their six-monthly booster dose within the normal designated timeframe.
Equip Artervac is indicated for the active immunisation for horses against equine arteritis virus to reduce the clinical signs and shedding of virus in nasal secretions following infection.
For further information, contact your Zoetis Account Manager or the Zoetis Technical Team on customersupportUK@zoetis.com or 0845 300 9084 choosing option 1.
Buprelieve is a 0.3mg/ml buprenorphine solution for injection, licensed for post-operative analgesia and to potentiate the sedative effects of other centrally-acting agents in dogs and horses. It can be administered by intramuscular or intravenous injection to dogs and cats and by intravenous injection to horses and is available in 10ml multi-dose glass vials.
Dr Rich Irvine BVSc MRCVS, veterinary services manager at Jurox (UK) Limited said: "We are delighted to be extending our range of products with the launch of Buprelieve which will provide veterinary practices with effective and economical analgesia.
"The launch of Buprelieve will be supported by our highly qualified team of veterinary surgeons who aim to deliver top quality help, advice and assistance for clinics wishing to perform best practice anaesthesia across all patient groups."
Jurox says it has been listening to the concerns of veterinary surgeons who say they want high quality generic medicines at affordable prices along with transparency as to what they are paying for each vial. As a result, the company says it is launching Buprelieve at a very affordable list price with a simple and generous introductory offer or rebate.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "Jurox prides itself on providing customers with a range of high quality medicines and we believe the launch of Buprelieve will also satisfy vets’ increasing requests for competitively priced products. We understand that providing high quality pain relief is critical and Buprelieve helps vets deliver the care they demand for their patients."
For more information, contact your local Jurox technical advisor, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
Till then, veterinary surgeons are advised to make due diligent attempts to source a UK-authorised product before considering importing an alternative medicine.
Procaine hydrochloride is used in farm animal medicine in particular, to provide local and regional anaesthesia for a range of procedures including calving, lambing, caesarean operations, castration and dehorning of cattle, with demand particularly high in the spring.
Simon Doherty, BVA President, said: "We’re pleased that VMD has issued some clarification to answer our concerns over procaine hydrochloride shortages. BVA had heard from some veterinary practices that they were only able to get hold of a fraction of what they needed, which would have resulted in a very acute impact on farm animal welfare. Although we had moved to get assurances sooner, we appreciate that there are formal routes for reporting and that the announcement of any shortage must be handled sensitively to avoid exacerbating the problem.
"VMD’s clarification is especially timely as this is a period of peak seasonal demand for these products. We will keep our members closely informed of any further developments."
Novartis Animal Health has announced that it will begin marketing and distributing Adequan Equine in the UK from January 2011.
According to the company, Adequan Equine offers equine veterinarians a proven intramuscular treatment option for equine degenerative joint disease, also known as non-infectious arthritis or osteoarthritis. The product is licensed in the UK for the treatment of lameness in horses due to traumatic or degenerative aseptic joint disease and acute superficial digital flexor tendonitis. This is a critical treatment area since equine degenerative joint disease is estimated to cause up to one-third of all equine lameness cases1. It most commonly affects the hocks and coffin joints with the most severe effects on the high-motion knee and fetlock joints.
Esther Rawlinson MRCVS, Global Technical Services Manager for the Novartis Animal Health Companion Animal Business in the Therapeutics & Equine areas said: "Adequan Equine is a leading joint treatment for horses and is widely used by veterinarians in the equine sport industry. Adequan Equine reduces pain and lameness in horses while at the same time stimulating cartilage repair.
Adequan Equine 100mg/ml solution contains polysulphated glycosaminoglycan for intramuscular injection. It is a chondroprotective, meaning it inhibits the breakdown of cartilage in diseased joints while at the same time supporting its repair.
Adequan Equine works by blocking the destructive enzymes formed in the joint as a result of inflammation while stimulating the production of hyaluronic acid to restore the synovial fluid, and the synthesis of cartilage building compounds.
Eurovet Animal Health Ltd has entered the UK veterinary pharmaceuticals market with a portfolio of products including a levothyroxine tablet for the treatment of canine hypothyroidism, injectables for cattle and pigs, a xylazine injection for use in cattle, horses, dogs & cats and a corticosteroid for use in horses, cattle, pigs, cats and dogs.
Eurovet Animal Health is a subsidiary of Dutch company, AUV, which was established in 1969 as a cooperative by 100 veterinary surgeons, and is now jointly owned by 2000 vets. The company says this gives it a unique perspective on the products that veterinary surgeons really need and want. And whilst Eurovet Animal Health is still relatively small in the UK, the parent company Eurovet Animal Health BV owns state-of-the-art manufacturing facilities and provides access to international expertise, support and resources.
Eurovet Animal Health Ltd will be offering Eurovet products previously distributed by partner companies in the UK, so vets can expect to see brands they know and trust, as well as new brands. Existing products will be available from veterinary wholesalers and include:
Further information about Eurovet's range of products is available from Eurovet Animal Health, Compass House, Chivers Way, Histon, Cambridge, CB24 9AD Tel: 01223 257933 E-mail office@eurovet-ah.co.uk http://www.eurovet-ah.co.uk/
Pfizer has repeated it's call for veterinary practice staff to take part in its Vet Support+ independent, industry-wide survey of employee engagement.
The survey gives practice team members, who are not partners or owners, the chance to have their say about their role and career and the future of the profession. Participants are asked to consider how they feel towards their practice and delve into issues on teamwork and communication, management techniques, personal development opportunities and working environment.
More than 3,000 vet practice staff have already completed the survey, a phenomenal early response which suggests practice employees are keen to have their voices heard. However, the closing date for the survey isn't till Friday 29th July, so if you haven't yet had a chance to do the survey, there is still time.
Pfizer Business Consultant, Vanessa Wilson, has more than 20 years experience helping businesses, teams and individuals achieve their goals. She is not surprised at the significant early response: "Questions on the level of employee engagement and satisfaction come up all the time in the work we do with practices. I'm not surprised that staff are using this opportunity to have their voice heard.
"Once completed, this survey will provide some very useful data and direction for the industry as a whole and I'd like to think it will identify opportunities for both individual career development and practice growth."
All members of staff employed within a practice who have not received a mailing and wish to participate are welcome to respond online. http://www.noesis-mi.com/surveys/employeesurvey/.
Pfizer says the findings, which are expected to be released in the autumn, will deliver a national and regional view of the current employee engagement landscape.
For further information about Vet Support+ Business Services from Pfizer visit www.vetsupportplus.co.uk.